CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Fecal Calprotectin Testing Coverage Criteria

This policy governs coverage and clinical use of fecal calprotectin testing for evaluation and management of suspected or known inflammatory bowel disease (IBD) for members of Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyFecal Calprotectin Testing Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionOrdering physicians must handle authorization, appeals, and related administrative processes; laboratories must not obtain authorization on the physician’s behalf.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

83993CPT code specified for fecal calprotectin

93%-99%sensitivity at ~50 µg/g

50 µg/gcommon lower-bound cutoff

152 µg/grelapse prediction cutoff

66.7%colonoscopies avoided

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Fecal Calprotectin Testing

Initial diagnostic evaluation (when endoscopy being considered)

Medically necessary indication for evaluation when endoscopy with biopsy is being considered

Indication: Fecal calprotectin testing is medically necessary for evaluation of individuals when the differential diagnosis is inflammatory bowel disease (IBD) versus noninflammatory bowel disease (including irritable bowel syndrome) and endoscopy with biopsy is being considered.50 µg/g commonly used

Testing can inform decision to proceed with endoscopy; evidence shows high sensitivity (93%–99%) at ~50 µg/g and can reduce need for colonoscopy by ~66.7%.

Monitoring and surveillance (active disease and remission)

Management and monitoring of established IBD

Active disease monitoring: Fecal calprotectin testing for monitoring disease activity in individuals with established active IBD is considered not covered / not medically necessary because current evidence is insufficient to demonstrate improved health outcomes when management is guided by calprotectin levels.50 µg/g referenced as triage threshold in reviews

Randomized controlled trials have not isolated an independent benefit from calprotectin-guided treatment changes; existing RCTs either included calprotectin among multiple indicators or used home tests with limited applicability.

Surveillance in remission: Fecal calprotectin testing to predict relapse or for routine surveillance in IBD patients in remission is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products due to insufficient evidence that testing improves clinical outcomes.~152 µg/g reported as an optimal cutoff in relapse prediction meta-analysis (cutoff not universally established)

Studies show calprotectin may rise 2–3 months before relapse but ideal cutoff and impact on outcomes are unproven; RCTs have not demonstrated outcome improvements.

Benefits and coverage for fecal calprotectin testing may vary by group and contract. Self-funded groups may have specific contract exclusions affecting biomarker and genetic testing coverage; providers should consult the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement to confirm coverage details. Refer to related policies (e.g., Biomarker Testing Mandate, Genetic Testing Services) for additional contract- and program-specific rules.

Fecal calprotectin testing is not covered for Medicare Advantage Plans and is considered not medically necessary for Commercial Products when used for the management of established inflammatory bowel disease (including monitoring active disease and surveillance for relapse in remission), because the evidence is insufficient to demonstrate improved health outcomes. Randomized trials and systematic reviews have not established that calprotectin-guided management improves symptoms, relapse rates, quality of life, hospitalizations, or other patient-centered outcomes.

Coding and Cutoffs

Covered CPT CodesCPTCovered

83993

Calprotectin, fecal

ICD-10 Codes that may support medical necessityICD-10

K52.3
K52.89
K52.9
K58.0
K58.1
K58.2
K58.3
K58.4
K58.5
K58.6

1–10 of 17

1/2

Fecal calprotectin cutoffs — inv-07

Common diagnostic lower-bound50 µg/g (most diagnostic studies used this cutoff; recommended lower bound)

Relapse prediction optimal cutoff152 µg/g (pooled optimal cut-off reported in a meta-analysis of 24 prospective studies)

Sensitivity at ~50 µg/g93%–99% sensitivity for IBD detection reported in studies using 50 µg/g

Predictive performance for relapsePooled sensitivity 72% and specificity 74% at ~152 µg/g

Provider Actions, Authorization, and Billing

Prior Authorization

Authorization process responsibility

Prior authorization is not applicable for this policy. Laboratories are not permitted to obtain clinical authorization or participate in the authorization process on behalf of the ordering physician. Only the ordering physician shall be involved in authorization, appeal, or other administrative processes related to prior authorization/medical necessity. If a laboratory provides a laboratory service that has not been authorized, the service will be denied as the financial liability of the participating laboratory and may not be billed to the member.

Only the ordering physician may request authorizations or file appeals; laboratories and laboratory representatives must not obtain or facilitate authorizations on behalf of the ordering physician.
If a laboratory or third party supports any portion of the authorization process, BCBSRI will treat this as a policy violation and may take severe action up to termination from the provider network.
Unauthorized laboratory services will be denied and the participating laboratory is financially liable; these services may not be billed to the member.

Note

Prior authorization verification

This policy is informational and does not itself specify prior authorization codes or processes. Providers should verify prior authorization and benefit/eligibility requirements for the member's specific plan prior to providing services by contacting the BCBSRI provider call center or using the payer's standard authorization tools.

Clinical Background

Fecal calprotectin is a stool biomarker that reflects neutrophilic intestinal inflammation and can help distinguish inflammatory bowel disease (IBD) from noninflammatory conditions such as irritable bowel syndrome. It is measurable using ELISA or immunoturbidimetric assays and has been used for diagnosis, monitoring treatment response, and predicting relapse. Many diagnostic studies have used a lower-bound cutoff of 50 µg/g for triaging symptomatic patients for endoscopy, and a meta-analysis reported an optimal cutoff of approximately 152 µg/g for predicting relapse, though ideal thresholds vary by indication and assay. While calprotectin levels often rise 2–3 months before clinical relapse, randomized controlled trial evidence is insufficient to show that routine calprotectin-guided management leads to improved clinical outcomes.

Definitions

Calprotectin — inv-17

DefinitionCalprotectin is a calcium- and zinc-binding protein released from neutrophils during activation or apoptosis/necrosis, and constitutes approximately 60% of neutrophil cytoplasmic proteins.

Role in inflammationReleased during neutrophil activation or cell death and involved in regulating inflammatory processes.

Stability in fecesStable in feces at room temperature for up to 1 week, allowing home collection and laboratory submission.

Inflammatory bowel disease (IBD) — inv-18

Definition of IBDInflammatory bowel disease (IBD) encompasses Crohn disease and ulcerative colitis, chronic conditions with differing distributions and depths of GI tract inflammation.

Clinical featuresSymptoms may be gastrointestinal (eg, abdominal pain, bloody diarrhea, perianal fistulae), systemic (eg, weight loss, fatigue), or extraintestinal (eg, rashes, uveitis, arthritis).